目的 比较托拉塞米和丹参酮Ⅱ_A磺酸钠治疗慢性充血性心力衰竭的临床疗效。方法 选取2014年1月-2015年12月在邢台市第三医院治疗的慢性充血性心力衰竭患者78例，随机分为对照组和治疗组，每组各39例。对照组静脉注射丹参酮Ⅱ_A磺酸钠注射液，20 mg/次，1次/d。治疗组静脉注射托拉塞米注射液，20 mg/次，1次/d。两组均连续治疗7 d。观察两组的临床疗效，比较两组B型脑钠肽（BNP）、血浆肾素（PRA）、血管紧张素Ⅱ（AngⅡ）、醛固酮（ALD）和左心室肥厚指标。结果 治疗后，对照组和治疗组的总有效率分别为69.2%、87.2%，两组比较差异有统计学意义（P<0.05）。治疗后，两组BNP、PRA、AngⅡ和ALD水平均有明显下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的下降程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组左室后壁舒张末期厚度（LVPWT）、左室舒张末期内径（LVDD）和室间隔舒张末期厚度（IVST）均有明显下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的下降程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 托拉塞米治疗慢性充血性心力衰竭的临床疗效优于丹参酮Ⅱ_A磺酸钠，能降低血浆BNP、PRA、AngⅡ和ALD水平，改善左心室肥厚，安全性较好，具有一定的临床推广应用价值。

Objective To compare the clinical efficacy between torasemide and sulfotanshinone sodium in treatment of chronic congestive heart failure. Methods Patients (78 cases) with chronic congestive heart failure in Xingtai Third Hospital from January 2013 to February 2015 were randomly divided into control and treatment groups, and each group had 39 cases. Patients in the control group were iv administered with Sulfotanshinone Sodium Injection, 20 mg/time, once daily. Patients in the treatment group were iv administered with Torsemide Injection, 20 mg/time, once daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacies were evaluated, and BNP, PRA, Ang Ⅱ, ALD, and left ventricular hypertrophy indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 69.2% and 87.2%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of BNP, PRA, Ang Ⅱ, and ALD in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, LVPWT, LVDD and IVST in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion The clinical curative effect of torasemide in treatment of chronic congestive heart failure was better than that of sulfotanshinone Sodium, can decrease the levels of BNP, PRA, Ang Ⅱ, and ALD, and improve left ventricular hypertrophy, with good safety, which has a certain clinical application value.